CRADA Sample Clauses

CRADA. Concurrently with entry into this Agreement, the parties agree to the obligations set forth in Exhibit B, which is hereby made a part hereof of this Agreement, pursuant to which NewLink will provide certain funding to LIMR in support of the Sponsored Research to be conducted by the Investigators. Under such CRADA, NewLink may renew the Sponsored Research (Newlink shall base its election upon the research results and other potential corporate limitations) for additional years at an annual budget to be based on scientific needs and approved by NewLink; [*] described in Exhibit B, in consideration for such funding LIMR agrees to [*] for Future IDO Discoveries as provided in Section 13 (b). The decision to renew the CRADA for additional years shall be made at least three months prior to the expiration date of the CRADA and shall based on a progress report submitted by LIMR to NewLink.
AutoNDA by SimpleDocs
CRADA. The term "CRADA" means any agreement between one or more federal laboratories (e.g., the Coast Guard Research and Development Center, the Coast Guard Academy, etc.) and one or more non-federal parties under which the government, through its laboratories, provides personnel, services, facilities, equipment, intellectual property, or other resources with or without reimbursement, (but not funds to non-federal parties). Non-federal parties provide funds, personnel, services, facilities, equipment, intellectual property, or other resources toward the conduct of specified research or development efforts which are consistent with the missions of the laboratory. The term CRADA does not include a procurement contract or cooperative agreement as those terms are used in §§ 6303-6305 of title 31, United States Code. Federal agencies, in accordance with Reference (a) may permit the director of any government-operated federal laboratory to enter into agreements on behalf of the agency with the following:
CRADA. The term “CRADA” shall mean the Cooperative Research and Development Agreement for Non-Hodgkin Lymphoma Therapeutic Cancer Vaccine between Biovest and the National Cancer Institute.
CRADA. Attached as Exhibit 3.27 is a copy of the CRADA. Except as set forth in Exhibit 3.27: (i) the CRADA is in good standing, (ii) Biovest is in full compliance with all material terms and requirements of the CRADA, (iii) Biovest has not received any notice of default or non-compliance of or with the CRADA, and (iv) Biovest has no reason to believe that it may be in default or non-compliance, with the CRADA.
CRADA. A Cooperative Research and Development Agreement (CRADA) is a “comprehensive legal [agreement] for the sharing of personnel, equipment, funding, and intellectual property rights in joint government-industry research.”42 CRADAs can be made with other government agencies (local, state, and federal), private companies, foundations, universities, or individuals.43 In such an agreement, both parties share the costs of R&D and have the ability to negotiate the licensing of any inventions that come out of it.44 These arrangements are fairly common: in 2005, the DOD alone had more than 2,000 CRADAs.45 CRADAs do have some potential as a tool for creating innovation orchards, as they allow technology entrepreneurs access to the resources possessed by national laboratories. For this reason, many PIAs, including the examples of N-STEP and TechLink, contain within them the option for the government agency involved to enter into a CRADA with businesses identified by the PI.46 However, there are also a number of issues with CRADAs that would prevent them from being enough to form innovation orchards on their own. Los Alamos National Laboratory is home to a number of CRADAs. When 63 individuals from the lab and 59 individuals from the private companies that they were in a CRADA agreement with were asked in 1998 what the biggest obstacles to the process of entering a CRADA were, the majority of both groups chose “complicated administrative procedures.”47 More than 40% of each group also identified “the lengthy time period to establish a CRADA” as one of the major obstacles.48 According to other research, “CRADA negotiations take about two to four months when no complicated issues are raised. However, when legal [or technology] complications arise, negotiations often last from four to six months and in some instances from twelve to eighteen months.”49 Because “time spent in planning joint R&D [is charged] to a laboratory's overhead account… lab researchers often spend their own time working on a CRADA.”50 CRADAs can often be a useful tool, but the administrative and organizational difficulties inherent in the way they are structured could make it difficult to create the type of truly cooperative environment necessary for an innovation orchard to thrive using this device alone. Keeping CRADAs as one tool in the box of a PIA appears a good idea, but relying on that tool alone may not.

Related to CRADA

  • Research Collaboration Upon FibroGen’s request, the Parties will discuss conducting a research program funded by AstraZeneca and directed toward franchise enhancement and lifecycle management for HIF Compounds or other topics that the Parties determine relevant to the Products and the Field. Upon agreement on the terms of such research program, the Parties will enter into a separate agreement or amend this Agreement accordingly.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Joint Inventions For Subject Inventions conceived or first actually reduced to practice under this Agreement that are joint Subject Inventions made by CONTRACTOR and USER, each Party shall have the option to elect and retain title to its undivided rights in such joint Subject Inventions.

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

Time is Money Join Law Insider Premium to draft better contracts faster.